Mr Mrs Miss Ms Dr Other

Dr
Nienke
Lubben

Partner & Patent Attorney

York Office The Hague Office

Life sciences

Telephone. +44(0) 1904 732 120
Mobile. +44(0) 777 265 2294
Email. nlubben@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.

Experience

Nienke is a European and UK Patent Attorney. Her client base includes several universities, start-ups, independent research institutes and small to medium enterprises. She advises on IP portfolio management and strategy, drafting, patent prosecution, freedom to operate and due diligence relating to potential asset licencing, acquisition or investment. Her extensive experience in drafting and analysing the value of third party patents and patent applications has given her a good understanding of how to prepare patent applications that are attractive to potential investors and licensees. In terms of technologies, Nienke specialises in the field of cell and gene therapy, with particular experience in TCR and CAR-T cell therapies. She has experience in a diverse range of technical subject matter including antibody and peptide therapeutics, viral vector production, biomarkers and diagnostic methods. She has a PhD in cell biology and immunology.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Biological Sciences (genetics)

PHD

Cell Biology and Immunology

Recognition

Publications

Managing Intellectual Property firm rankings - IP Stars 2024

View publication online

MIP IP Rising Stars 2019/20

View publication online

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.